FindTrial
Sign In

The effects of long-term oral ACEI or ARB drugs on disease outcome and nucleic acid transition time in hypertensive patients infected with Omicron: a retrospective study

Effects of long-term oral ACEI or ARB drugs on disease outcome and nucleic acid negative conversion time in hypertensive patients infected with Omicron

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061804
Enrollment
Unknown
Registered
2022-07-03
Start date
2022-07-10
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Experimental group:ACEI/ARB treatment
Control group:Other hypotensive drugs treatment

Sponsors

Shanghai Fourth People's Hospital, Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. COVID-19 patients confirmed by the diagnostic criteria and clinical staging method of COVID-19 Diagnosis and Treatment Protocol (Trial Edition 9) (includ asymptomatic, mild, normal, severe, critical); 2. Patients complicated with essential hypertension and regularly taking antihypertensive drugs for >= 1 month.

Exclusion criteria

Exclusion criteria: 1. Survival time after hospitalization <= 48 hours; 2. The time of virus nucleic acid positive or negative cannot be determined.

Design outcomes

Primary

MeasureTime frame
Length of hospital stay;Length of nucleic acid turning negative;—

Secondary

MeasureTime frame
organ functions;Hospital admission;Total hospitalization;—

Countries

China

Contacts

Public ContactChen Hui

Shanghai Fourth People's Hospital, Tongji University

chenhui_md@163.com+86 13003131393

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026